Analysts predict that Zosano Pharma Corp (NASDAQ:ZSAN) will post ($0.24) earnings per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Zosano Pharma’s earnings. Zosano Pharma posted earnings per share of ($0.46) during the same quarter last year, which indicates a positive year-over-year growth rate of 47.8%. The firm is expected to announce its next earnings results on Wednesday, March 7th.

According to Zacks, analysts expect that Zosano Pharma will report full year earnings of ($0.90) per share for the current financial year. For the next fiscal year, analysts expect that the firm will report earnings of ($0.90) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Zosano Pharma.

Zosano Pharma (NASDAQ:ZSAN) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.05).

Separately, ValuEngine raised shares of Zosano Pharma from a “strong sell” rating to a “sell” rating in a research note on Sunday, December 31st.

In other news, Director Kenneth Greathouse purchased 95,000 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were bought at an average cost of $0.62 per share, with a total value of $58,900.00. Following the purchase, the director now directly owns 95,000 shares of the company’s stock, valued at $58,900. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have acquired a total of 200,000 shares of company stock worth $123,450 over the last ninety days. 2.95% of the stock is owned by corporate insiders.

An institutional investor recently raised its position in Zosano Pharma stock. Northern Trust Corp boosted its holdings in Zosano Pharma Corp (NASDAQ:ZSAN) by 591.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 79,234 shares of the biotechnology company’s stock after buying an additional 67,774 shares during the period. Northern Trust Corp owned approximately 0.20% of Zosano Pharma worth $112,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.41% of the company’s stock.

Shares of Zosano Pharma (ZSAN) traded down $0.01 during midday trading on Monday, reaching $0.57. 443,859 shares of the company were exchanged, compared to its average volume of 670,986. Zosano Pharma has a 12-month low of $0.50 and a 12-month high of $3.54. The firm has a market cap of $22.89, a PE ratio of -0.49 and a beta of 2.50.

TRADEMARK VIOLATION NOTICE: “Brokerages Anticipate Zosano Pharma Corp (ZSAN) to Announce -$0.24 Earnings Per Share” was first reported by Marea Informative and is the property of of Marea Informative. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at

About Zosano Pharma

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

Get a free copy of the Zacks research report on Zosano Pharma (ZSAN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with's FREE daily email newsletter.